nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Melphalan—hematologic cancer	0.301	1	CrCtD
L-DOPA—PSIP1—hematologic cancer	0.252	1	CbGaD
L-DOPA—Melphalan—Chlorambucil—hematologic cancer	0.125	0.741	CrCrCtD
L-DOPA—SLC7A5—Melphalan—hematologic cancer	0.121	0.814	CbGbCtD
L-DOPA—L-Tyrosine—Melphalan—hematologic cancer	0.0306	0.181	CrCrCtD
L-DOPA—L-Phenylalanine—Melphalan—hematologic cancer	0.013	0.0769	CrCrCtD
L-DOPA—CYP2D6—Lomustine—hematologic cancer	0.00521	0.0352	CbGbCtD
L-DOPA—CYP2D6—Idarubicin—hematologic cancer	0.00465	0.0314	CbGbCtD
L-DOPA—CYP2D6—Hydroxyurea—hematologic cancer	0.00395	0.0267	CbGbCtD
L-DOPA—CYP2D6—Bortezomib—hematologic cancer	0.00344	0.0232	CbGbCtD
L-DOPA—CYP2D6—Imatinib—hematologic cancer	0.00252	0.017	CbGbCtD
L-DOPA—CYP2D6—Nilotinib—hematologic cancer	0.00229	0.0154	CbGbCtD
L-DOPA—CYP2D6—Vinorelbine—hematologic cancer	0.00227	0.0153	CbGbCtD
L-DOPA—CYP2D6—Vinblastine—hematologic cancer	0.0014	0.00944	CbGbCtD
L-DOPA—PSIP1—hematopoietic system—hematologic cancer	0.00125	0.0802	CbGeAlD
L-DOPA—CYP2D6—Dexamethasone—hematologic cancer	0.00104	0.00699	CbGbCtD
L-DOPA—PSIP1—gonad—hematologic cancer	0.000949	0.061	CbGeAlD
L-DOPA—CYP2D6—Doxorubicin—hematologic cancer	0.000859	0.0058	CbGbCtD
L-DOPA—PSIP1—blood—hematologic cancer	0.000827	0.0531	CbGeAlD
L-DOPA—PSIP1—bone marrow—hematologic cancer	0.0008	0.0514	CbGeAlD
L-DOPA—PSIP1—lung—hematologic cancer	0.000725	0.0466	CbGeAlD
L-DOPA—DRD5—hematopoietic system—hematologic cancer	0.000685	0.044	CbGeAlD
L-DOPA—PSIP1—testis—hematologic cancer	0.000684	0.044	CbGeAlD
L-DOPA—SLC7A5—hematopoietic system—hematologic cancer	0.000638	0.041	CbGeAlD
L-DOPA—SLC7A8—gonad—hematologic cancer	0.000626	0.0402	CbGeAlD
L-DOPA—DRD4—testis—hematologic cancer	0.00057	0.0366	CbGeAlD
L-DOPA—L-Histidine—HDC—hematologic cancer	0.000564	0.317	CrCbGaD
L-DOPA—PSIP1—lymph node—hematologic cancer	0.000496	0.0319	CbGeAlD
L-DOPA—SLC16A10—hematopoietic system—hematologic cancer	0.000488	0.0314	CbGeAlD
L-DOPA—SLC7A5—gonad—hematologic cancer	0.000485	0.0311	CbGeAlD
L-DOPA—SLC7A8—lung—hematologic cancer	0.000478	0.0307	CbGeAlD
L-DOPA—SLC7A8—testis—hematologic cancer	0.000451	0.029	CbGeAlD
L-DOPA—SLC7A5—blood—hematologic cancer	0.000423	0.0271	CbGeAlD
L-DOPA—DDC—lung—hematologic cancer	0.000414	0.0266	CbGeAlD
L-DOPA—SLC7A5—bone marrow—hematologic cancer	0.000409	0.0263	CbGeAlD
L-DOPA—DDC—testis—hematologic cancer	0.00039	0.0251	CbGeAlD
L-DOPA—SLC16A10—gonad—hematologic cancer	0.000371	0.0239	CbGeAlD
L-DOPA—SLC7A5—lung—hematologic cancer	0.00037	0.0238	CbGeAlD
L-DOPA—SLC7A5—testis—hematologic cancer	0.00035	0.0225	CbGeAlD
L-DOPA—Mimosine—CCL2—hematologic cancer	0.000331	0.187	CrCbGaD
L-DOPA—SLC7A8—lymph node—hematologic cancer	0.000327	0.021	CbGeAlD
L-DOPA—SLC16A10—blood—hematologic cancer	0.000324	0.0208	CbGeAlD
L-DOPA—SLC16A10—lung—hematologic cancer	0.000284	0.0182	CbGeAlD
L-DOPA—DDC—lymph node—hematologic cancer	0.000283	0.0182	CbGeAlD
L-DOPA—PSIP1—Podofilox—Teniposide—hematologic cancer	0.000272	0.192	CbGdCrCtD
L-DOPA—SLC16A10—testis—hematologic cancer	0.000268	0.0172	CbGeAlD
L-DOPA—SLC7A5—lymph node—hematologic cancer	0.000253	0.0163	CbGeAlD
L-DOPA—Isoprenaline—PIK3R1—hematologic cancer	0.000214	0.12	CrCbGaD
L-DOPA—PSIP1—Menadione—Thalidomide—hematologic cancer	0.000206	0.145	CbGdCrCtD
L-DOPA—SLC16A10—lymph node—hematologic cancer	0.000194	0.0125	CbGeAlD
L-DOPA—CYP2D6—hematopoietic system—hematologic cancer	0.000186	0.0119	CbGeAlD
L-DOPA—DRD2—lung—hematologic cancer	0.00018	0.0115	CbGeAlD
L-DOPA—DRD2—testis—hematologic cancer	0.000169	0.0109	CbGeAlD
L-DOPA—PSIP1—Teniposide—Etoposide—hematologic cancer	0.000162	0.114	CbGdCrCtD
L-DOPA—PSIP1—Podofilox—Etoposide—hematologic cancer	0.000162	0.114	CbGdCrCtD
L-DOPA—PSIP1—Vinblastine—Vinorelbine—hematologic cancer	0.000139	0.0981	CbGdCrCtD
L-DOPA—SLC7A5—Tretinoin—Alitretinoin—hematologic cancer	0.000138	0.0973	CbGdCrCtD
L-DOPA—SLC7A5—Isotretinoin—Alitretinoin—hematologic cancer	0.000138	0.0973	CbGdCrCtD
L-DOPA—Masoprocol—ALOX5—hematologic cancer	0.00013	0.0733	CrCbGaD
L-DOPA—CYP2D6—blood—hematologic cancer	0.000123	0.0079	CbGeAlD
L-DOPA—Aminosalicylic Acid—ALOX5—hematologic cancer	0.000121	0.0681	CrCbGaD
L-DOPA—PSIP1—Vinblastine—Vincristine—hematologic cancer	0.000111	0.0785	CbGdCrCtD
L-DOPA—CYP2D6—testis—hematologic cancer	0.000102	0.00654	CbGeAlD
L-DOPA—Mesalazine—ALOX5—hematologic cancer	9.5e-05	0.0535	CrCbGaD
L-DOPA—Aminosalicylic Acid—MPO—hematologic cancer	7.8e-05	0.0439	CrCbGaD
L-DOPA—Mesalazine—MPO—hematologic cancer	6.12e-05	0.0345	CrCbGaD
L-DOPA—Norepinephrine—SLC22A1—hematologic cancer	4.26e-05	0.024	CrCbGaD
L-DOPA—Dopamine—SLC22A1—hematologic cancer	3.96e-05	0.0223	CrCbGaD
L-DOPA—Epinephrine—SLC22A1—hematologic cancer	3.86e-05	0.0217	CrCbGaD
L-DOPA—Epinephrine—TNF—hematologic cancer	2.78e-05	0.0157	CrCbGaD
L-DOPA—SLC7A5—Desoximetasone—Dexamethasone—hematologic cancer	1.88e-05	0.0133	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Betamethasone—hematologic cancer	1.88e-05	0.0133	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Triamcinolone—hematologic cancer	1.84e-05	0.013	CbGdCrCtD
L-DOPA—Liothyronine—ALB—hematologic cancer	1.76e-05	0.0099	CrCbGaD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—hematologic cancer	1.74e-05	0.0123	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Prednisolone—hematologic cancer	1.7e-05	0.012	CbGdCrCtD
L-DOPA—Liothyronine—ABCB1—hematologic cancer	1.68e-05	0.00945	CrCbGaD
L-DOPA—Flushing—Epirubicin—hematologic cancer	9.52e-06	0.000131	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—hematologic cancer	9.52e-06	0.000131	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—hematologic cancer	9.49e-06	0.00013	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisolone—hematologic cancer	9.45e-06	0.00013	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—hematologic cancer	9.45e-06	0.00013	CcSEcCtD
L-DOPA—Dyspepsia—Dexamethasone—hematologic cancer	9.42e-06	0.000129	CcSEcCtD
L-DOPA—Dyspepsia—Betamethasone—hematologic cancer	9.42e-06	0.000129	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—hematologic cancer	9.37e-06	0.000129	CcSEcCtD
L-DOPA—Urticaria—Triamcinolone—hematologic cancer	9.37e-06	0.000129	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—hematologic cancer	9.35e-06	0.000128	CcSEcCtD
L-DOPA—Asthenia—Etoposide—hematologic cancer	9.33e-06	0.000128	CcSEcCtD
L-DOPA—Oedema—Prednisone—hematologic cancer	9.32e-06	0.000128	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—hematologic cancer	9.31e-06	0.000128	CcSEcCtD
L-DOPA—Decreased appetite—Betamethasone—hematologic cancer	9.3e-06	0.000128	CcSEcCtD
L-DOPA—Decreased appetite—Dexamethasone—hematologic cancer	9.3e-06	0.000128	CcSEcCtD
L-DOPA—Nausea—Mitoxantrone—hematologic cancer	9.29e-06	0.000127	CcSEcCtD
L-DOPA—Nausea—Irinotecan—hematologic cancer	9.29e-06	0.000127	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Dexamethasone—hematologic cancer	9.24e-06	0.000127	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Betamethasone—hematologic cancer	9.24e-06	0.000127	CcSEcCtD
L-DOPA—Back pain—Methotrexate—hematologic cancer	9.23e-06	0.000127	CcSEcCtD
L-DOPA—Fatigue—Dexamethasone—hematologic cancer	9.23e-06	0.000127	CcSEcCtD
L-DOPA—Fatigue—Betamethasone—hematologic cancer	9.23e-06	0.000127	CcSEcCtD
L-DOPA—Pruritus—Etoposide—hematologic cancer	9.2e-06	0.000126	CcSEcCtD
L-DOPA—Shock—Prednisone—hematologic cancer	9.17e-06	0.000126	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—hematologic cancer	9.17e-06	0.000126	CcSEcCtD
L-DOPA—Pain—Dexamethasone—hematologic cancer	9.15e-06	0.000126	CcSEcCtD
L-DOPA—Pain—Betamethasone—hematologic cancer	9.15e-06	0.000126	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—hematologic cancer	9.07e-06	0.000124	CcSEcCtD
L-DOPA—Nausea—Gemcitabine—hematologic cancer	9.05e-06	0.000124	CcSEcCtD
L-DOPA—Vomiting—Cisplatin—hematologic cancer	9.02e-06	0.000124	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisone—hematologic cancer	9.01e-06	0.000124	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—hematologic cancer	8.99e-06	0.000123	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—hematologic cancer	8.99e-06	0.000123	CcSEcCtD
L-DOPA—Rash—Cisplatin—hematologic cancer	8.95e-06	0.000123	CcSEcCtD
L-DOPA—Dermatitis—Cisplatin—hematologic cancer	8.94e-06	0.000123	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—hematologic cancer	8.9e-06	0.000122	CcSEcCtD
L-DOPA—Anorexia—Prednisone—hematologic cancer	8.88e-06	0.000122	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—hematologic cancer	8.85e-06	0.000121	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—hematologic cancer	8.82e-06	0.000121	CcSEcCtD
L-DOPA—Feeling abnormal—Betamethasone—hematologic cancer	8.82e-06	0.000121	CcSEcCtD
L-DOPA—Feeling abnormal—Dexamethasone—hematologic cancer	8.82e-06	0.000121	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—hematologic cancer	8.81e-06	0.000121	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—hematologic cancer	8.8e-06	0.000121	CcSEcCtD
L-DOPA—Tension—Epirubicin—hematologic cancer	8.76e-06	0.00012	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dexamethasone—hematologic cancer	8.75e-06	0.00012	CcSEcCtD
L-DOPA—Gastrointestinal pain—Betamethasone—hematologic cancer	8.75e-06	0.00012	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—hematologic cancer	8.75e-06	0.00012	CcSEcCtD
L-DOPA—Hypersensitivity—Triamcinolone—hematologic cancer	8.69e-06	0.000119	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—hematologic cancer	8.67e-06	0.000119	CcSEcCtD
L-DOPA—Back pain—Epirubicin—hematologic cancer	8.64e-06	0.000118	CcSEcCtD
L-DOPA—Malaise—Methotrexate—hematologic cancer	8.61e-06	0.000118	CcSEcCtD
L-DOPA—Dizziness—Etoposide—hematologic cancer	8.6e-06	0.000118	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—hematologic cancer	8.59e-06	0.000118	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—hematologic cancer	8.54e-06	0.000117	CcSEcCtD
L-DOPA—Urticaria—Dexamethasone—hematologic cancer	8.5e-06	0.000117	CcSEcCtD
L-DOPA—Urticaria—Betamethasone—hematologic cancer	8.5e-06	0.000117	CcSEcCtD
L-DOPA—Dizziness—Prednisolone—hematologic cancer	8.48e-06	0.000116	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—hematologic cancer	8.48e-06	0.000116	CcSEcCtD
L-DOPA—Asthenia—Triamcinolone—hematologic cancer	8.46e-06	0.000116	CcSEcCtD
L-DOPA—Abdominal pain—Dexamethasone—hematologic cancer	8.46e-06	0.000116	CcSEcCtD
L-DOPA—Abdominal pain—Betamethasone—hematologic cancer	8.46e-06	0.000116	CcSEcCtD
L-DOPA—Nausea—Cisplatin—hematologic cancer	8.43e-06	0.000116	CcSEcCtD
L-DOPA—Insomnia—Prednisone—hematologic cancer	8.43e-06	0.000116	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—hematologic cancer	8.42e-06	0.000115	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—hematologic cancer	8.39e-06	0.000115	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—hematologic cancer	8.37e-06	0.000115	CcSEcCtD
L-DOPA—Pruritus—Triamcinolone—hematologic cancer	8.34e-06	0.000114	CcSEcCtD
L-DOPA—Cough—Methotrexate—hematologic cancer	8.33e-06	0.000114	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—hematologic cancer	8.32e-06	0.000114	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—hematologic cancer	8.29e-06	0.000114	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—hematologic cancer	8.27e-06	0.000113	CcSEcCtD
L-DOPA—Vomiting—Etoposide—hematologic cancer	8.27e-06	0.000113	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—hematologic cancer	8.25e-06	0.000113	CcSEcCtD
L-DOPA—Agitation—Epirubicin—hematologic cancer	8.21e-06	0.000113	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—hematologic cancer	8.2e-06	0.000113	CcSEcCtD
L-DOPA—Rash—Etoposide—hematologic cancer	8.2e-06	0.000112	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—hematologic cancer	8.19e-06	0.000112	CcSEcCtD
L-DOPA—Headache—Etoposide—hematologic cancer	8.15e-06	0.000112	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—hematologic cancer	8.14e-06	0.000112	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—hematologic cancer	8.12e-06	0.000111	CcSEcCtD
L-DOPA—Tension—Doxorubicin—hematologic cancer	8.11e-06	0.000111	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—hematologic cancer	8.1e-06	0.000111	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—hematologic cancer	8.09e-06	0.000111	CcSEcCtD
L-DOPA—Rash—Prednisolone—hematologic cancer	8.09e-06	0.000111	CcSEcCtD
L-DOPA—Dermatitis—Prednisolone—hematologic cancer	8.08e-06	0.000111	CcSEcCtD
L-DOPA—Malaise—Epirubicin—hematologic cancer	8.05e-06	0.00011	CcSEcCtD
L-DOPA—Fatigue—Prednisone—hematologic cancer	8.03e-06	0.00011	CcSEcCtD
L-DOPA—Headache—Prednisolone—hematologic cancer	8.03e-06	0.00011	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—hematologic cancer	8.03e-06	0.00011	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—hematologic cancer	8.03e-06	0.00011	CcSEcCtD
L-DOPA—Syncope—Epirubicin—hematologic cancer	8.01e-06	0.00011	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—hematologic cancer	7.99e-06	0.00011	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—hematologic cancer	7.99e-06	0.00011	CcSEcCtD
L-DOPA—Constipation—Prednisone—hematologic cancer	7.97e-06	0.000109	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—hematologic cancer	7.94e-06	0.000109	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—hematologic cancer	7.89e-06	0.000108	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—hematologic cancer	7.85e-06	0.000108	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—hematologic cancer	7.85e-06	0.000108	CcSEcCtD
L-DOPA—Dizziness—Triamcinolone—hematologic cancer	7.8e-06	0.000107	CcSEcCtD
L-DOPA—Cough—Epirubicin—hematologic cancer	7.79e-06	0.000107	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—hematologic cancer	7.79e-06	0.000107	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—hematologic cancer	7.74e-06	0.000106	CcSEcCtD
L-DOPA—Nausea—Etoposide—hematologic cancer	7.72e-06	0.000106	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—hematologic cancer	7.71e-06	0.000106	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisone—hematologic cancer	7.68e-06	0.000105	CcSEcCtD
L-DOPA—Asthenia—Dexamethasone—hematologic cancer	7.68e-06	0.000105	CcSEcCtD
L-DOPA—Asthenia—Betamethasone—hematologic cancer	7.68e-06	0.000105	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—hematologic cancer	7.67e-06	0.000105	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—hematologic cancer	7.64e-06	0.000105	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—hematologic cancer	7.63e-06	0.000105	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—hematologic cancer	7.62e-06	0.000105	CcSEcCtD
L-DOPA—Nausea—Prednisolone—hematologic cancer	7.62e-06	0.000104	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—hematologic cancer	7.6e-06	0.000104	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—hematologic cancer	7.59e-06	0.000104	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—hematologic cancer	7.58e-06	0.000104	CcSEcCtD
L-DOPA—Pruritus—Dexamethasone—hematologic cancer	7.57e-06	0.000104	CcSEcCtD
L-DOPA—Pruritus—Betamethasone—hematologic cancer	7.57e-06	0.000104	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—hematologic cancer	7.53e-06	0.000103	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—hematologic cancer	7.51e-06	0.000103	CcSEcCtD
L-DOPA—Vomiting—Triamcinolone—hematologic cancer	7.5e-06	0.000103	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—hematologic cancer	7.45e-06	0.000102	CcSEcCtD
L-DOPA—Rash—Triamcinolone—hematologic cancer	7.44e-06	0.000102	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—hematologic cancer	7.44e-06	0.000102	CcSEcCtD
L-DOPA—Dermatitis—Triamcinolone—hematologic cancer	7.43e-06	0.000102	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—hematologic cancer	7.42e-06	0.000102	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—hematologic cancer	7.41e-06	0.000102	CcSEcCtD
L-DOPA—Urticaria—Prednisone—hematologic cancer	7.4e-06	0.000102	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—hematologic cancer	7.4e-06	0.000101	CcSEcCtD
L-DOPA—Headache—Triamcinolone—hematologic cancer	7.39e-06	0.000101	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—hematologic cancer	7.37e-06	0.000101	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—hematologic cancer	7.35e-06	0.000101	CcSEcCtD
L-DOPA—Diarrhoea—Betamethasone—hematologic cancer	7.32e-06	0.0001	CcSEcCtD
L-DOPA—Diarrhoea—Dexamethasone—hematologic cancer	7.32e-06	0.0001	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—hematologic cancer	7.3e-06	0.0001	CcSEcCtD
L-DOPA—Oedema—Epirubicin—hematologic cancer	7.29e-06	0.0001	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—hematologic cancer	7.28e-06	9.98e-05	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—hematologic cancer	7.26e-06	9.96e-05	CcSEcCtD
L-DOPA—Cough—Doxorubicin—hematologic cancer	7.21e-06	9.89e-05	CcSEcCtD
L-DOPA—Shock—Epirubicin—hematologic cancer	7.17e-06	9.84e-05	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—hematologic cancer	7.16e-06	9.82e-05	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—hematologic cancer	7.14e-06	9.79e-05	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—hematologic cancer	7.13e-06	9.79e-05	CcSEcCtD
L-DOPA—Dizziness—Betamethasone—hematologic cancer	7.08e-06	9.71e-05	CcSEcCtD
L-DOPA—Dizziness—Dexamethasone—hematologic cancer	7.08e-06	9.71e-05	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—hematologic cancer	7.05e-06	9.66e-05	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—hematologic cancer	7.04e-06	9.66e-05	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—hematologic cancer	7.04e-06	9.65e-05	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—hematologic cancer	7.01e-06	9.62e-05	CcSEcCtD
L-DOPA—Nausea—Triamcinolone—hematologic cancer	7.01e-06	9.61e-05	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—hematologic cancer	6.99e-06	9.59e-05	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—hematologic cancer	6.95e-06	9.53e-05	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—hematologic cancer	6.95e-06	9.53e-05	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—hematologic cancer	6.94e-06	9.52e-05	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—hematologic cancer	6.92e-06	9.5e-05	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—hematologic cancer	6.88e-06	9.44e-05	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—hematologic cancer	6.87e-06	9.42e-05	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—hematologic cancer	6.86e-06	9.4e-05	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—hematologic cancer	6.81e-06	9.34e-05	CcSEcCtD
L-DOPA—Vomiting—Betamethasone—hematologic cancer	6.8e-06	9.33e-05	CcSEcCtD
L-DOPA—Vomiting—Dexamethasone—hematologic cancer	6.8e-06	9.33e-05	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—hematologic cancer	6.8e-06	9.33e-05	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—hematologic cancer	6.77e-06	9.29e-05	CcSEcCtD
L-DOPA—Rash—Dexamethasone—hematologic cancer	6.75e-06	9.25e-05	CcSEcCtD
L-DOPA—Rash—Betamethasone—hematologic cancer	6.75e-06	9.25e-05	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—hematologic cancer	6.74e-06	9.25e-05	CcSEcCtD
L-DOPA—Dermatitis—Betamethasone—hematologic cancer	6.74e-06	9.25e-05	CcSEcCtD
L-DOPA—Dermatitis—Dexamethasone—hematologic cancer	6.74e-06	9.25e-05	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.72e-06	9.22e-05	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—hematologic cancer	6.72e-06	9.21e-05	CcSEcCtD
L-DOPA—Headache—Dexamethasone—hematologic cancer	6.7e-06	9.2e-05	CcSEcCtD
L-DOPA—Headache—Betamethasone—hematologic cancer	6.7e-06	9.2e-05	CcSEcCtD
L-DOPA—Asthenia—Prednisone—hematologic cancer	6.69e-06	9.17e-05	CcSEcCtD
L-DOPA—Pain—Methotrexate—hematologic cancer	6.66e-06	9.14e-05	CcSEcCtD
L-DOPA—Shock—Doxorubicin—hematologic cancer	6.64e-06	9.1e-05	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—hematologic cancer	6.6e-06	9.06e-05	CcSEcCtD
L-DOPA—Pruritus—Prednisone—hematologic cancer	6.59e-06	9.04e-05	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—hematologic cancer	6.59e-06	9.04e-05	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—hematologic cancer	6.55e-06	8.98e-05	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—hematologic cancer	6.52e-06	8.94e-05	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—hematologic cancer	6.5e-06	8.91e-05	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—hematologic cancer	6.48e-06	8.89e-05	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—hematologic cancer	6.43e-06	8.82e-05	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—hematologic cancer	6.42e-06	8.8e-05	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—hematologic cancer	6.42e-06	8.8e-05	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—hematologic cancer	6.38e-06	8.75e-05	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—hematologic cancer	6.37e-06	8.74e-05	CcSEcCtD
L-DOPA—Nausea—Betamethasone—hematologic cancer	6.36e-06	8.72e-05	CcSEcCtD
L-DOPA—Nausea—Dexamethasone—hematologic cancer	6.36e-06	8.72e-05	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—hematologic cancer	6.34e-06	8.69e-05	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—hematologic cancer	6.3e-06	8.64e-05	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.29e-06	8.63e-05	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—hematologic cancer	6.28e-06	8.62e-05	CcSEcCtD
L-DOPA—Pain—Epirubicin—hematologic cancer	6.23e-06	8.55e-05	CcSEcCtD
L-DOPA—Constipation—Epirubicin—hematologic cancer	6.23e-06	8.55e-05	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—hematologic cancer	6.19e-06	8.49e-05	CcSEcCtD
L-DOPA—Dizziness—Prednisone—hematologic cancer	6.16e-06	8.45e-05	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—hematologic cancer	6.16e-06	8.45e-05	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—hematologic cancer	6.1e-06	8.37e-05	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—hematologic cancer	6.06e-06	8.31e-05	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—hematologic cancer	6.01e-06	8.25e-05	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—hematologic cancer	6.01e-06	8.24e-05	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—hematologic cancer	6e-06	8.22e-05	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—hematologic cancer	5.96e-06	8.18e-05	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—hematologic cancer	5.94e-06	8.14e-05	CcSEcCtD
L-DOPA—Vomiting—Prednisone—hematologic cancer	5.93e-06	8.13e-05	CcSEcCtD
L-DOPA—Rash—Prednisone—hematologic cancer	5.88e-06	8.06e-05	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—hematologic cancer	5.87e-06	8.05e-05	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—hematologic cancer	5.86e-06	8.04e-05	CcSEcCtD
L-DOPA—Headache—Prednisone—hematologic cancer	5.84e-06	8.01e-05	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.82e-06	7.99e-05	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—hematologic cancer	5.81e-06	7.98e-05	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—hematologic cancer	5.79e-06	7.94e-05	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—hematologic cancer	5.77e-06	7.91e-05	CcSEcCtD
L-DOPA—Pain—Doxorubicin—hematologic cancer	5.77e-06	7.91e-05	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—hematologic cancer	5.76e-06	7.9e-05	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—hematologic cancer	5.74e-06	7.87e-05	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—hematologic cancer	5.59e-06	7.66e-05	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—hematologic cancer	5.56e-06	7.62e-05	CcSEcCtD
L-DOPA—Nausea—Prednisone—hematologic cancer	5.54e-06	7.59e-05	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.51e-06	7.56e-05	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—hematologic cancer	5.51e-06	7.56e-05	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—hematologic cancer	5.37e-06	7.37e-05	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—hematologic cancer	5.36e-06	7.35e-05	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—hematologic cancer	5.33e-06	7.31e-05	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—hematologic cancer	5.33e-06	7.31e-05	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—hematologic cancer	5.23e-06	7.17e-05	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—hematologic cancer	5.16e-06	7.07e-05	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—hematologic cancer	5.15e-06	7.06e-05	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—hematologic cancer	4.99e-06	6.84e-05	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—hematologic cancer	4.97e-06	6.82e-05	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—hematologic cancer	4.95e-06	6.79e-05	CcSEcCtD
L-DOPA—Rash—Methotrexate—hematologic cancer	4.91e-06	6.74e-05	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—hematologic cancer	4.91e-06	6.73e-05	CcSEcCtD
L-DOPA—Headache—Methotrexate—hematologic cancer	4.88e-06	6.69e-05	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—hematologic cancer	4.84e-06	6.64e-05	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—hematologic cancer	4.82e-06	6.61e-05	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—hematologic cancer	4.77e-06	6.54e-05	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—hematologic cancer	4.63e-06	6.36e-05	CcSEcCtD
L-DOPA—Nausea—Methotrexate—hematologic cancer	4.63e-06	6.35e-05	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—hematologic cancer	4.61e-06	6.33e-05	CcSEcCtD
L-DOPA—Rash—Epirubicin—hematologic cancer	4.6e-06	6.3e-05	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—hematologic cancer	4.59e-06	6.3e-05	CcSEcCtD
L-DOPA—Headache—Epirubicin—hematologic cancer	4.57e-06	6.26e-05	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—hematologic cancer	4.46e-06	6.12e-05	CcSEcCtD
L-DOPA—Nausea—Epirubicin—hematologic cancer	4.33e-06	5.94e-05	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—hematologic cancer	4.29e-06	5.88e-05	CcSEcCtD
L-DOPA—Rash—Doxorubicin—hematologic cancer	4.25e-06	5.83e-05	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—hematologic cancer	4.25e-06	5.83e-05	CcSEcCtD
L-DOPA—Headache—Doxorubicin—hematologic cancer	4.23e-06	5.8e-05	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—hematologic cancer	4.01e-06	5.49e-05	CcSEcCtD
L-DOPA—DRD2—Signaling by GPCR—JAK2—hematologic cancer	1.23e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FN1—hematologic cancer	1.23e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JUN—hematologic cancer	1.23e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREBBP—hematologic cancer	1.22e-06	3.2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HES1—hematologic cancer	1.22e-06	3.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH1—hematologic cancer	1.22e-06	3.18e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BAD—hematologic cancer	1.21e-06	3.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NFKBIA—hematologic cancer	1.21e-06	3.17e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NCOR1—hematologic cancer	1.21e-06	3.16e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH1—hematologic cancer	1.2e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGF1—hematologic cancer	1.2e-06	3.13e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CSF2—hematologic cancer	1.2e-06	3.13e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CD80—hematologic cancer	1.19e-06	3.12e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KIT—hematologic cancer	1.19e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—hematologic cancer	1.19e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—hematologic cancer	1.19e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1A—hematologic cancer	1.19e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—hematologic cancer	1.19e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FOXO1—hematologic cancer	1.18e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—hematologic cancer	1.18e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFRB—hematologic cancer	1.18e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CD80—hematologic cancer	1.18e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—hematologic cancer	1.17e-06	3.07e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KIT—hematologic cancer	1.17e-06	3.07e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—hematologic cancer	1.17e-06	3.07e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAP2K1—hematologic cancer	1.17e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTPN11—hematologic cancer	1.17e-06	3.06e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CB—hematologic cancer	1.16e-06	3.05e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CD—hematologic cancer	1.16e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK8—hematologic cancer	1.16e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFRA—hematologic cancer	1.16e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—hematologic cancer	1.16e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JAK1—hematologic cancer	1.15e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCG—hematologic cancer	1.15e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTPN11—hematologic cancer	1.15e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—hematologic cancer	1.15e-06	3.01e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK3—hematologic cancer	1.14e-06	2.98e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—hematologic cancer	1.14e-06	2.97e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREB1—hematologic cancer	1.13e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EP300—hematologic cancer	1.13e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK3—hematologic cancer	1.12e-06	2.94e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—hematologic cancer	1.12e-06	2.92e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREB1—hematologic cancer	1.12e-06	2.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGF2—hematologic cancer	1.11e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—hematologic cancer	1.11e-06	2.9e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6R—hematologic cancer	1.1e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—hematologic cancer	1.1e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREBBP—hematologic cancer	1.1e-06	2.88e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NQO1—hematologic cancer	1.1e-06	2.88e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CD44—hematologic cancer	1.1e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—hematologic cancer	1.1e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3R1—hematologic cancer	1.1e-06	2.87e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—hematologic cancer	1.09e-06	2.86e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6R—hematologic cancer	1.09e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREBBP—hematologic cancer	1.09e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2RA—hematologic cancer	1.08e-06	2.82e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—hematologic cancer	1.07e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—hematologic cancer	1.07e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JAK2—hematologic cancer	1.07e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—hematologic cancer	1.07e-06	2.79e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—hematologic cancer	1.06e-06	2.77e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—hematologic cancer	1.06e-06	2.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAP2K1—hematologic cancer	1.05e-06	2.75e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CD—hematologic cancer	1.05e-06	2.74e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—hematologic cancer	1.04e-06	2.73e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYCS—hematologic cancer	1.04e-06	2.72e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—hematologic cancer	1.04e-06	2.72e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFB—hematologic cancer	1.04e-06	2.72e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—hematologic cancer	1.04e-06	2.72e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAP2K1—hematologic cancer	1.04e-06	2.72e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.04e-06	2.71e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.03e-06	2.71e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CD—hematologic cancer	1.03e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—hematologic cancer	1.02e-06	2.68e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—hematologic cancer	1.02e-06	2.67e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSC2—hematologic cancer	1.02e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK3—hematologic cancer	1.01e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MTOR—hematologic cancer	1.01e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CB—hematologic cancer	1.01e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—hematologic cancer	1.01e-06	2.64e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGF2—hematologic cancer	1e-06	2.62e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGF2—hematologic cancer	9.88e-07	2.58e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3R1—hematologic cancer	9.87e-07	2.58e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—hematologic cancer	9.85e-07	2.58e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—hematologic cancer	9.82e-07	2.57e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR3—hematologic cancer	9.78e-07	2.56e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3R1—hematologic cancer	9.74e-07	2.55e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK14—hematologic cancer	9.68e-07	2.53e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—hematologic cancer	9.66e-07	2.53e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JAK2—hematologic cancer	9.59e-07	2.51e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1B—hematologic cancer	9.5e-07	2.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—hematologic cancer	9.5e-07	2.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JAK2—hematologic cancer	9.47e-07	2.48e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—hematologic cancer	9.4e-07	2.46e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—hematologic cancer	9.4e-07	2.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FN1—hematologic cancer	9.38e-07	2.45e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—hematologic cancer	9.37e-07	2.45e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—hematologic cancer	9.31e-07	2.44e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—hematologic cancer	9.3e-07	2.43e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—hematologic cancer	9.28e-07	2.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKBIA—hematologic cancer	9.27e-07	2.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BAD—hematologic cancer	9.27e-07	2.43e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—hematologic cancer	9.25e-07	2.42e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—hematologic cancer	9.24e-07	2.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH1—hematologic cancer	9.18e-07	2.4e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—hematologic cancer	9.18e-07	2.4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MTOR—hematologic cancer	9.11e-07	2.38e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CB—hematologic cancer	9.11e-07	2.38e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—hematologic cancer	9.1e-07	2.38e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—hematologic cancer	9.06e-07	2.37e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JUN—hematologic cancer	9.04e-07	2.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CD80—hematologic cancer	8.99e-07	2.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MTOR—hematologic cancer	8.99e-07	2.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CB—hematologic cancer	8.99e-07	2.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—hematologic cancer	8.98e-07	2.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KIT—hematologic cancer	8.98e-07	2.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—hematologic cancer	8.98e-07	2.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTPN11—hematologic cancer	8.82e-07	2.31e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1A—hematologic cancer	8.77e-07	2.29e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—hematologic cancer	8.75e-07	2.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—hematologic cancer	8.7e-07	2.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—hematologic cancer	8.69e-07	2.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK3—hematologic cancer	8.6e-07	2.25e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—hematologic cancer	8.58e-07	2.25e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK8—hematologic cancer	8.56e-07	2.24e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1B—hematologic cancer	8.55e-07	2.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREB1—hematologic cancer	8.55e-07	2.24e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—hematologic cancer	8.53e-07	2.23e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—hematologic cancer	8.46e-07	2.21e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—hematologic cancer	8.44e-07	2.21e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1B—hematologic cancer	8.44e-07	2.21e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NCOR1—hematologic cancer	8.43e-07	2.21e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—hematologic cancer	8.43e-07	2.21e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—hematologic cancer	8.38e-07	2.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—hematologic cancer	8.37e-07	2.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—hematologic cancer	8.36e-07	2.19e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—hematologic cancer	8.36e-07	2.19e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—hematologic cancer	8.35e-07	2.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EP300—hematologic cancer	8.34e-07	2.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6R—hematologic cancer	8.34e-07	2.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—hematologic cancer	8.33e-07	2.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREBBP—hematologic cancer	8.32e-07	2.18e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—hematologic cancer	8.27e-07	2.16e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—hematologic cancer	8.26e-07	2.16e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—hematologic cancer	8.22e-07	2.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—hematologic cancer	8.16e-07	2.13e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JUN—hematologic cancer	8.14e-07	2.13e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—hematologic cancer	8.11e-07	2.12e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—hematologic cancer	8.09e-07	2.12e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—hematologic cancer	8.05e-07	2.11e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JUN—hematologic cancer	8.03e-07	2.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAP2K1—hematologic cancer	7.95e-07	2.08e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—hematologic cancer	7.9e-07	2.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CD—hematologic cancer	7.89e-07	2.07e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1A—hematologic cancer	7.89e-07	2.06e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—hematologic cancer	7.87e-07	2.06e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—hematologic cancer	7.82e-07	2.05e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—hematologic cancer	7.82e-07	2.05e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—hematologic cancer	7.8e-07	2.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1A—hematologic cancer	7.79e-07	2.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—hematologic cancer	7.77e-07	2.03e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—hematologic cancer	7.73e-07	2.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—hematologic cancer	7.73e-07	2.02e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK8—hematologic cancer	7.7e-07	2.02e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—hematologic cancer	7.68e-07	2.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK8—hematologic cancer	7.6e-07	1.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—hematologic cancer	7.58e-07	1.98e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGF2—hematologic cancer	7.56e-07	1.98e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EP300—hematologic cancer	7.51e-07	1.96e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK3—hematologic cancer	7.47e-07	1.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—hematologic cancer	7.45e-07	1.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3R1—hematologic cancer	7.45e-07	1.95e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EP300—hematologic cancer	7.41e-07	1.94e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—hematologic cancer	7.4e-07	1.94e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—hematologic cancer	7.3e-07	1.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—hematologic cancer	7.27e-07	1.9e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—hematologic cancer	7.25e-07	1.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JAK2—hematologic cancer	7.24e-07	1.9e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—hematologic cancer	7.2e-07	1.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—hematologic cancer	7.11e-07	1.86e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—hematologic cancer	7.1e-07	1.86e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—hematologic cancer	7.07e-07	1.85e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—hematologic cancer	7.04e-07	1.84e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—hematologic cancer	7.02e-07	1.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—hematologic cancer	7.02e-07	1.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—hematologic cancer	6.95e-07	1.82e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—hematologic cancer	6.93e-07	1.81e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MTOR—hematologic cancer	6.88e-07	1.8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	6.88e-07	1.8e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—hematologic cancer	6.83e-07	1.79e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK3—hematologic cancer	6.73e-07	1.76e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—hematologic cancer	6.72e-07	1.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK3—hematologic cancer	6.64e-07	1.74e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—hematologic cancer	6.57e-07	1.72e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—hematologic cancer	6.54e-07	1.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—hematologic cancer	6.53e-07	1.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	6.46e-07	1.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—hematologic cancer	6.46e-07	1.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—hematologic cancer	6.44e-07	1.69e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	6.39e-07	1.67e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—hematologic cancer	6.33e-07	1.66e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—hematologic cancer	6.32e-07	1.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—hematologic cancer	6.29e-07	1.64e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—hematologic cancer	6.26e-07	1.64e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	6.17e-07	1.61e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—hematologic cancer	6.16e-07	1.61e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JUN—hematologic cancer	6.15e-07	1.61e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—hematologic cancer	6.05e-07	1.58e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—hematologic cancer	5.97e-07	1.56e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—hematologic cancer	5.97e-07	1.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	5.96e-07	1.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—hematologic cancer	5.94e-07	1.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK8—hematologic cancer	5.82e-07	1.52e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CREBBP—hematologic cancer	5.81e-07	1.52e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—hematologic cancer	5.8e-07	1.52e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—hematologic cancer	5.71e-07	1.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EP300—hematologic cancer	5.67e-07	1.48e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	5.55e-07	1.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—hematologic cancer	5.51e-07	1.44e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CD—hematologic cancer	5.51e-07	1.44e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	5.48e-07	1.43e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—hematologic cancer	5.46e-07	1.43e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—hematologic cancer	5.44e-07	1.42e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—hematologic cancer	5.37e-07	1.41e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—hematologic cancer	5.37e-07	1.4e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—hematologic cancer	5.32e-07	1.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—hematologic cancer	5.3e-07	1.39e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—hematologic cancer	5.3e-07	1.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3R1—hematologic cancer	5.2e-07	1.36e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—hematologic cancer	5.14e-07	1.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK3—hematologic cancer	5.08e-07	1.33e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—hematologic cancer	5.07e-07	1.33e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—hematologic cancer	5.04e-07	1.32e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—hematologic cancer	4.94e-07	1.29e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—hematologic cancer	4.93e-07	1.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—hematologic cancer	4.92e-07	1.29e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—hematologic cancer	4.85e-07	1.27e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CB—hematologic cancer	4.8e-07	1.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—hematologic cancer	4.56e-07	1.19e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—hematologic cancer	4.54e-07	1.19e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—hematologic cancer	4.48e-07	1.17e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	4.19e-07	1.1e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—hematologic cancer	4.15e-07	1.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—hematologic cancer	4.06e-07	1.06e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—EP300—hematologic cancer	3.95e-07	1.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—hematologic cancer	3.88e-07	1.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—hematologic cancer	3.71e-07	9.72e-06	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—hematologic cancer	3.43e-07	8.96e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—hematologic cancer	2.93e-07	7.65e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—hematologic cancer	2.39e-07	6.25e-06	CbGpPWpGaD
